^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
...FOLFIRI with panitumumab is listed as an option for first-line therapy in mCRC...the combination of FOLFOX and panitumumab remains an option as initial therapy for patients with advanced or metastatic disease.
Secondary therapy:
FOLFOX; FOLFIRI
Source:
Title:
FDA Grants Priority Review of Panitumumab for Treatment of Patients with Metastatic Colorectal Cancer
Published date:
06/12/2006
Excerpt:
Amgen...announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologic License Application (BLA) for panitumumab, an investigational fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFr) and has granted Priority Review.
Source:
Title:
Abgenix and Amgen Announce FDA Grants Panitumumab Fast Track Designation for Metastatic Colorectal Cancer
Published date:
08/01/2005
Excerpt:
Amgen (Nasdaq:AMGN) and Abgenix, Inc. (Nasdaq:ABGX) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for panitumumab, an experimental fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFr), for patients with metastatic colorectal cancer who have failed standard chemotherapy treatment.
